Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Akebia Therapeutics ( (AKBA) ) has issued an announcement.
On March 19, 2025, Akebia Therapeutics announced the pricing of its public offering of 25 million shares of common stock at $2.00 per share, aiming to raise approximately $50 million before expenses. The offering, managed by Leerink Partners and Piper Sandler, is expected to close on March 21, 2025, and includes an option for underwriters to purchase an additional 3.75 million shares. Akebia anticipates net proceeds of $46.5 million, which could increase to $53.6 million if the additional shares are fully purchased, supporting its goal of achieving profitability.
More about Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on improving the lives of individuals affected by kidney disease. Founded in 2007, the company is headquartered in Cambridge, Massachusetts.
YTD Price Performance: 49.47%
Average Trading Volume: 2,722,622
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $602.4M
For detailed information about AKBA stock, go to TipRanks’ Stock Analysis page.